en · de · es · pt
cjc-1295-notes.peptides3081.com › Topic › Receptor Action And Pharmacokinetics — Common Mistakes

Receptor Action And Pharmacokinetics — Common Mistakes

By Editorial Desk · published 2026-05-21 · last reviewed 2026-06-23 · Topic

The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-06-23 and is reviewed periodically as new material appears.

Receptor Action and Pharmacokinetics

CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.

The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.

Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.

Identity and Naming History

CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.

The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.

Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.

Cjc-1295 at a glance

PropertyValueNotes
Primary targetGHRH receptorG-protein-coupled receptor on pituitary somatotrophs
Half-life, long-acting formSeveral daysExtended by covalent albumin binding
Half-life, short formAbout 30 minutesCleared rapidly by peptidases and kidneys
Route in studiesSubcutaneous injectionUsed in the published human trials
Main measured effectRise in GH and IGF-1Surrogate markers rather than clinical endpoints

Background and Molecular Design

The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.

Related pages on this site

Handling Storage and Quality Control

Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.

Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.

Notes from published material

Hird returned to court in early November 2014, and his appeal was dismissed on 29 January 2015. Hird considered a High Court appeal, but on 27 February 2015 announced that he had decided against proceeding.

Antihistamines (or "histamine antagonists") inhibit the release or action of histamine. "Antihistamine" can be used to describe any histamine antagonist, but the term is usually reserved for the classical antihistamines that act upon the H1 histamine receptor. Antihistamines are used as treatment for allergies. Allergies are caused by an excessive response of the body to allergens, such as the pollen released by grasses and trees. An allergic reaction causes release of histamine by the body. Other uses of antihistamines are to help with normal symptoms of insect stings even if there is no allergic reaction. Their recreational appeal exists mainly due to their anticholinergic properties, that induce anxiolysis and, in some cases such as diphenhydramine, chlorpheniramine, and orphenadrine, a characteristic euphoria at moderate doses. High dosages taken to induce recreational drug effects may lead to overdoses. Antihistamines are also consumed in combination with alcohol, particularly by youth who find it hard to obtain alcohol. The combination of the two drugs can cause intoxication with lower alcohol doses. Hallucinations and possibly delirium resembling the effects of Datura stramonium can result if the drug is taken in much higher than therapeutic doses. Antihistamines are widely available over the counter at drug stores (without a prescription), in the form of allergy medication and some cough medicines. They are sometimes used in combination with other substances such as alcohol.

=== Nanotechnology === Operando spectroscopy has become a vital tool for surface chemistry. Nanotechnology, used in materials science, involves active catalytic sites on a reagent surface with at least one dimension in the nano-scale of approximately 1–100 nm. As particle size decreases, surface area increases. This results in a more reactive catalytic surface. The reduced scale of these reactions affords several opportunities while presenting unique challenges; for example, due to the very small size of the crystals (sometimes <5 nm), any X-ray crystallography diffraction signal may be very weak. As catalysis is a surface process, one particular challenge in catalytic studies is resolving the typically weak spectroscopic signal of the catalytically active surface against that of the inactive bulk structure. Moving from the micro to the nano scale increases the surface to volume ratio of the particles, maximizing the signal of the surface relative to that of the bulk. Furthermore, as the scale of the reaction decreases towards nano scale, individual processes can be discerned that would otherwise be lost in the average signal of a bulk reaction composed of multiple coincident steps and species such as spectators, intermediates, and reactive sites.

Sources: en.wikipedia.org

Further detail

As of 2016, Mister Donut Japan had over "1,300 stores, making it the largest donut chain in the country." and as of June 2016, Duskin Co., Ltd. was also operating Mister Donut stores in China, Taiwan, South Korea, Thailand, the Philippines, Indonesia, Japan, and Malaysia. In 2020, Dunkin' Brands was purchased by Sandy Springs-based Inspire Brands, and Mister Donut's trademark management became part of Inspire.

Heterodimerization with ERAP2 Some experimental evidence has indicated the possibility of heterodimer formation between ERAP1 and ERAP2, another member of the oxytocinase sub-family of M1 aminopeptidases, that shares structural and functional similarities. The co-elution of ERAP1 and ERAP2 was detected through microsome fractionation, in the 230 kDa fraction, suggesting the formation of heterodimers. Proximity ligation assay analysis suggested a direct physical interaction between the two enzymes. A leucine zipper mediated ERAP1/ERAP2 complex exhibited enhanced trimming efficiency compared to a mixture of the two enzymes. Computational dynamics showed that ERAP1/ERAP2 heterodimerization could be mediated by the exon 10 loop, known to be involved in ERAP1-ERp44 interactions.

DBNPA (2,2-dibromo-3-nitrilopropionamide) is a brominated acetamide. Its synonyms include 2,2-dibromo-2-carbamoylacetonitrile, α,α-dibromo-α-cyanoacetamide, and dibromocyanoacetamide. The physical appearance of DBNPA is an off-white solid at ambient temperatures with a mild antiseptic odor and is often sold in powder form. DBNPA is often used as an algicide, bactericide and fungicide in industrial water treatment systems and as a preservative used in the manufacture of paper, glues, coatings, enhanced oil recovery systems and metalworking.

Sources: en.wikipedia.org

Frequently asked questions

How does CJC-1295 raise growth hormone levels?

It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.

Why does the DAC form last longer?

The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.

What remains uncertain about its effects?

Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.

Is this compound a naturally occurring hormone?

No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.

Network